TiGenix: An Undervalued Stem Cell Company Filing For A NASDAQ IPO – Seeking Alpha
Seeking Alpha |
TiGenix: An Undervalued Stem Cell Company Filing For A NASDAQ IPO
Seeking Alpha TiGenix is a leading stem cell biotech with one marketed product and one successful Phase 3 allogeneic treatment for Crohn's fistulas, Cx601, for which it just filed a MAA. Cx601 alone could represent a multi-billion dollar market opportunity in the U … |
